2 unknown, 1 completed. 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Unknown 1 |
| Phase 3 | 1 | Unknown 1 |
Follow KRM 1648: new trials by email Literature Review of KRM 1648 trials Research Report on KRM 1648
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy Study of Rifalazil for the Treatment of Chlamydia Trachomatis Infection in Women Rifalazil 25 milligram, Azithromycin 1 gram - Chlamydia Trachomatis Infection | Phase 2 | Completed | ActivBiotics Pharma, LLC | 82 | 2012-07-01 | 2013-04-29 |
| RESTORE-IT-Study of Rifalazil in Chlamydia Pneumoniae Seropositive Patients With a History of Atherosclerotic Disease Rifalazil - Coronary Artery Disease, Cerebrovascular Disease | Phase 2 | Unknown | ActivBiotics | 72 | 2006-10-01 | 2007-04-30 |
| PROVIDENCE-1: Study of Rifalazil in Chlamydia Pneumoniae Seropositive Patients Rifalazil - Peripheral Vascular Diseases, Intermittent Claudication | Phase 3 | Unknown | ActivBiotics | 274 | 2005-11-01 | 2008-08-21 |
Peripheral Vascular Diseases (2) · Cerebrovascular Disorders (1) · Chlamydia Infections (1) · Coronary Artery Disease (1) · Intermittent Claudication (1)
ActivBiotics (2) · ActivBiotics Pharma, LLC (1)
United States (3) · Brazil (1) · Canada (1) · Russia (1)